Atypical antipsychotics as a possible treatment option for irritable bowel syndrome

Chi Un Pae, Soo Jung Lee, Changsu Han, Ashwin A. Patkar, Prakash S. Masand

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs). Areas covered: With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS. Expert opinion: Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS.

Original languageEnglish
Pages (from-to)565-572
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number5
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Irritable Bowel Syndrome
Antipsychotic Agents
Tricyclic Antidepressive Agents
Therapeutics
Antidepressive Agents
Gastrointestinal Diseases
Major Depressive Disorder
Serotonin Uptake Inhibitors
Expert Testimony
Chronic Pain
Abdominal Pain
Habits
Psychiatry
Comorbidity
Sleep
Anxiety
Safety
Pain

Keywords

  • Anxiety
  • Atypical antipsychotic
  • Depression
  • Irritable bowel syndrome
  • Neurotransmitter

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. / Pae, Chi Un; Lee, Soo Jung; Han, Changsu; Patkar, Ashwin A.; Masand, Prakash S.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 5, 01.05.2013, p. 565-572.

Research output: Contribution to journalReview article

Pae, Chi Un ; Lee, Soo Jung ; Han, Changsu ; Patkar, Ashwin A. ; Masand, Prakash S. / Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22, No. 5. pp. 565-572.
@article{8c7ccf961ad2487c910b790e721451ab,
title = "Atypical antipsychotics as a possible treatment option for irritable bowel syndrome",
abstract = "Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs). Areas covered: With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS. Expert opinion: Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS.",
keywords = "Anxiety, Atypical antipsychotic, Depression, Irritable bowel syndrome, Neurotransmitter",
author = "Pae, {Chi Un} and Lee, {Soo Jung} and Changsu Han and Patkar, {Ashwin A.} and Masand, {Prakash S.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1517/13543784.2013.782392",
language = "English",
volume = "22",
pages = "565--572",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Atypical antipsychotics as a possible treatment option for irritable bowel syndrome

AU - Pae, Chi Un

AU - Lee, Soo Jung

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs). Areas covered: With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS. Expert opinion: Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS.

AB - Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs). Areas covered: With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS. Expert opinion: Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS.

KW - Anxiety

KW - Atypical antipsychotic

KW - Depression

KW - Irritable bowel syndrome

KW - Neurotransmitter

UR - http://www.scopus.com/inward/record.url?scp=84876255797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876255797&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.782392

DO - 10.1517/13543784.2013.782392

M3 - Review article

C2 - 23506326

AN - SCOPUS:84876255797

VL - 22

SP - 565

EP - 572

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -